LX-2006 is under clinical development by Lexeo Therapeutics and currently in Phase II for Cardiomyopathy. According to GlobalData, Phase II drugs for Cardiomyopathy have a 56% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how LX-2006’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
LX-2006 overview
LX-2006 is under development for the treatment of cardiomyopathy associated with Friedreich’s Ataxia. The drug candidate consists of Adeno-associated virus (AAV) vector carrying frataxin gene and is administered through intravenous route.
Lexeo Therapeutics overview
Lexeo Therapeutics (Lexeo), formerly Lexeo Therapeutics, is a clinical-stage genetic medicine company that develops therapies to treat cardiac and central nervous system disorders. The company is developing its lead product candidate, LX2006, to treat Friedreich’s ataxia (FA) and cardiomyopathy; and LX1001 for the treatment of APOE4 homozygous patients with Alzheimer’s disease. Its pipeline includes various drug candidates such as LX2021 to treat desmoplakin cardiomyopathy; LX2022 for hypertrophic cardiomyopathy; LX1021 against Alzheimer’s Christchurch; and LX1020 for the treatment of APOE4 homozygous patients. Lexeo collaborates with academic institutions for genetic medicines research related to AAV gene therapy and other therapeutic payload types and non-viral delivery systems. The company was funded by Sarepta Therapeutics. Lexeo is headquartered in New York, the US.
For a complete picture of LX-2006’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
